Coherus Oncology, Inc.CHRSEarnings & Financial Report
Coherus Oncology, Inc. is a commercial-stage biopharmaceutical company focused on developing, manufacturing and commercializing affordable oncology treatments, including FDA-approved biosimilars and novel targeted immuno-oncology therapies. Its core market is North America, serving patients with solid tumors and hematological malignancies to expand access to life-saving cancer care.
CHRS Q4 FY2025 Key Financial Metrics
Revenue
$12.7M
Gross Profit
$8.7M
Operating Profit
$-45.9M
Net Profit
$-37.6M
Gross Margin
68.3%
Operating Margin
-359.9%
Net Margin
-295.3%
YoY Growth
64.9%
EPS
$-0.34
Coherus Oncology, Inc. Q4 FY2025 Financial Summary
Coherus Oncology, Inc. reported revenue of $12.7M (up 64.9% YoY) for Q4 FY2025, with a net profit of $-37.6M (up 25.7% YoY) (-295.3% margin). Cost of goods sold was $4.0M, operating expenses totaled $54.6M.
Key Financial Metrics
| Total Revenue | $12.7M |
|---|---|
| Net Profit | $-37.6M |
| Gross Margin | 68.3% |
| Operating Margin | -359.9% |
| Report Period | Q4 FY2025 |
Revenue Breakdown
Coherus Oncology, Inc. Q4 FY2025 revenue of $12.7M breaks down across 2 segments, led by Toripalimab at $12.4M (97.0% of total).
| Segment | Revenue | % of Total |
|---|---|---|
| Toripalimab | $12.4M | 97.0% |
| Other | $388.0K | 3.0% |
Coherus Oncology, Inc. Revenue by Segment — Quarterly Trend
Coherus Oncology, Inc. revenue by segment across the last 4 reported quarters, showing how each business line (such as Toripalimab and Other) has evolved quarter over quarter.
| Segment | Q4 FY2025 | Q3 FY2025 | Q2 FY2025 | Q2 FY2024 |
|---|---|---|---|---|
| Toripalimab | $12.4M | — | $10.0M | — |
| Other | $388.0K | $908.0K | $295.0K | — |
Coherus Oncology, Inc. Annual Revenue by Year
Coherus Oncology, Inc. annual revenue history includes year-by-year totals (for example, 2022 revenue was $211.0M).
| Year | Annual Revenue | |
|---|---|---|
| 2022 | $211.0M | — |
Coherus Oncology, Inc. Quarterly Revenue & Net Profit History
Coherus Oncology, Inc. results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q4 FY2025 | $12.7M | +64.9% | $-37.6M | -295.3% |
| Q3 FY2025 | $11.6M | +91.2% | $-35.5M | -307.1% |
| Q2 FY2025 | $10.3M | -0.4% | $297.8M | 2903.9% |
| Q2 FY2024 | $10.3M | -82.5% | $-12.9M | -125.5% |
| Q3 FY2023 | $74.6M | +64.2% | $-39.6M | -53.2% |
| Q2 FY2023 | $58.7M | -2.4% | $-42.9M | -73.0% |
| Q1 FY2023 | $32.4M | -46.0% | $-75.7M | -233.5% |
| Q4 FY2022 | $45.4M | -38.2% | $-58.9M | -129.8% |
Income Statement
| Q4 2022 | Q1 2023 | Q2 2023 | Q3 2023 | Q2 2024 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $45.4M | $32.4M | $58.7M | $74.6M | $10.3M | $10.3M | $11.6M | $12.7M |
| YoY Growth | -38.2% | -46.0% | -2.4% | 64.2% | -82.5% | -0.4% | 91.2% | 64.9% |
Balance Sheet
| Q4 2022 | Q1 2023 | Q2 2023 | Q3 2023 | Q2 2024 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $480.8M | $402.4M | $469.6M | $583.8M | $674.9M | $439.5M | $516.5M | $258.3M |
| Liabilities | $618.3M | $598.9M | $644.4M | $717.4M | $759.0M | $319.6M | $428.7M | $197.3M |
| Equity | N/A | $-196.5M | $-174.8M | $-133.6M | $-84.1M | $119.8M | $87.8M | $61.0M |
Cash Flow
| Q4 2022 | Q1 2023 | Q2 2023 | Q3 2023 | Q2 2024 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $-100.0M | $-68.7M | $-38.9M | $-54.3M | $59.7M | $-46.6M | $-46.3M | $-19.7M |